Works matching IS 03407004 AND DT 2021 AND VI 70 AND IP 10
Results: 28
Correction to: CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3001, doi. 10.1007/s00262-021-03006-2
- By:
- Publication type:
- Article
Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3015, doi. 10.1007/s00262-021-02961-0
- By:
- Publication type:
- Article
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3041, doi. 10.1007/s00262-021-02938-z
- By:
- Publication type:
- Article
Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3031, doi. 10.1007/s00262-021-02935-2
- By:
- Publication type:
- Article
Correction to: Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited‑stage small cell lung cancer.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2991, doi. 10.1007/s00262-021-02910-x
- By:
- Publication type:
- Article
Tumor immune microenvironment in brain metastases from gynecologic malignancies.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2951, doi. 10.1007/s00262-021-02909-4
- By:
- Publication type:
- Article
Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2867, doi. 10.1007/s00262-021-02902-x
- By:
- Publication type:
- Article
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2911, doi. 10.1007/s00262-021-02901-y
- By:
- Publication type:
- Article
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2881, doi. 10.1007/s00262-021-02900-z
- By:
- Publication type:
- Article
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2893, doi. 10.1007/s00262-021-02898-4
- By:
- Publication type:
- Article
Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2737, doi. 10.1007/s00262-021-02897-5
- By:
- Publication type:
- Article
Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2835, doi. 10.1007/s00262-021-02896-6
- By:
- Publication type:
- Article
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2851, doi. 10.1007/s00262-021-02895-7
- By:
- Publication type:
- Article
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2937, doi. 10.1007/s00262-021-02894-8
- By:
- Publication type:
- Article
Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2795, doi. 10.1007/s00262-021-02891-x
- By:
- Publication type:
- Article
Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2981, doi. 10.1007/s00262-021-02890-y
- By:
- Publication type:
- Article
The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL).
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2961, doi. 10.1007/s00262-021-02889-5
- By:
- Publication type:
- Article
Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2771, doi. 10.1007/s00262-021-02888-6
- By:
- Publication type:
- Article
Brief in vitro IL-12 conditioning of CD8 <sup>+ </sup>T Cells for anticancer adoptive T cell therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2751, doi. 10.1007/s00262-021-02887-7
- By:
- Publication type:
- Article
TIGIT promotes CD8<sup>+</sup>T cells exhaustion and predicts poor prognosis of colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2781, doi. 10.1007/s00262-021-02886-8
- By:
- Publication type:
- Article
Combining UBR5 and CD163<sup>+</sup> tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2925, doi. 10.1007/s00262-021-02885-9
- By:
- Publication type:
- Article
Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2805, doi. 10.1007/s00262-021-02882-y
- By:
- Publication type:
- Article
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2761, doi. 10.1007/s00262-021-02880-0
- By:
- Publication type:
- Article
Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2819, doi. 10.1007/s00262-021-02877-9
- By:
- Publication type:
- Article
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2971, doi. 10.1007/s00262-021-02852-4
- By:
- Publication type:
- Article